MBRX - Moleculin gets U.S. patent issue notification for annamycin targeting unmet need in AML March, 27 2024 09:22 AM Moleculin Biotech Inc. 2024-03-27 09:22:30 ET More on Moleculin Biotech Moleculin Biotech, Inc. (MBRX) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Moleculin Biotech Historical earnings data for Moleculin Biotech Financial information for Moleculin Biotech For further details see: Moleculin gets U.S. patent issue notification for annamycin targeting unmet need in AML